Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats inflammatory lesions of rosacea. Sold as Epsolay. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Benzoyl Peroxide (sold as Epsolay), first approved Apr 22, 2022, with 0 new uses approved and 0 published complete response letters.
First approved: Apr 22, 2022
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $365K
First approved in Japan: Dec 26, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Epsolay
Part D
$365K
-21%
304
Approvals in Japan (PMDA)
First approved in Japan 88 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Bepio Wash, new approvalA drug with a new dosage in an additional dosage form indicated for the treatment of acne vulgaris. · Maruho Co., Ltd. · Mar 27, 2025
Bepio, new ingredientA drug with a new active ingredient indicated for the treatment of acne vulgaris. · Maruho Co., Ltd. · Dec 26, 2014
Clinical Trials
28 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
